Truly Tumor-Specific antibodies
Immediate Potential for Clinical-Stage Companies to Advance Cancer Therapies
All cancers have one thing in common -
a modification abundant in cancers but absent in healthy cells.
Healthy tissue
Tumor tissue
Combotopes' proprietary Antibody Discovery Platform generating antibodies with:
Tumor selectivity
High affinity
Flexibility
What does it mean ?
For Clinical Pharma:
Novel target candidates
Advancement of ADC and CAR
Untouched IP space
For Patients:
Better treatment options
Reduced side-effects
Improved life
Access to antibodies to novel and abundant tumor targets, fast and affordable discovery solutions, and an open IP space
EGFR, VEGFR, HER2, CD37, FLT3, FGFR, CD19, CD22, CD27, CD25, CD30, CD33, CD38, CD43, Mesothelin, PD-L1, CD44, Podocalyxin (TRA1.60/80), CD133, CD90, CD326, Cripto-1, ABCG2, CD24, CD49, Notch2, CD146 (MUC18), CD10, CD117, CD26, CXCR4, CD34, CD271, CD13, CD56, CD105, LGR5, CD114, CD54, CXCR1, TIM-3, CD55, DLL-4, CD96, CD29, CD9, CD166, CD44, ABCB5, Notch3, CD123, MUC1, MUC4, MUC16, MUC17, MUC21, CD33, CD40, Claudin-18, Integrin alpha-3, CK7, CK20, CXCR2, CXCR4, Integrin alpha-5, CA9, EPCAM, MET, MMP14, DDR1, NRP1, LAMP1-4, CD99, ALCAM, SDC1, 2, 3, 4, Syndecans (1-4), ITA5, ROBO1, Nectin-4, Nectin-2, LRP1, CD70, Podoplanin, IGF-1R, ABCG2, IBT1, ALK, TEM1, HVEM, TERT, LYPD3, GPR56, IL6RA, DDR1, LIFR, GPR64, S1PR1-4, LRCHD2, NMB, Plexin1/2, PTHR, Semaphorins, Slit3, TACD2, VGFC, VLDLR, VTN
〰️
EGFR, VEGFR, HER2, CD37, FLT3, FGFR, CD19, CD22, CD27, CD25, CD30, CD33, CD38, CD43, Mesothelin, PD-L1, CD44, Podocalyxin (TRA1.60/80), CD133, CD90, CD326, Cripto-1, ABCG2, CD24, CD49, Notch2, CD146 (MUC18), CD10, CD117, CD26, CXCR4, CD34, CD271, CD13, CD56, CD105, LGR5, CD114, CD54, CXCR1, TIM-3, CD55, DLL-4, CD96, CD29, CD9, CD166, CD44, ABCB5, Notch3, CD123, MUC1, MUC4, MUC16, MUC17, MUC21, CD33, CD40, Claudin-18, Integrin alpha-3, CK7, CK20, CXCR2, CXCR4, Integrin alpha-5, CA9, EPCAM, MET, MMP14, DDR1, NRP1, LAMP1-4, CD99, ALCAM, SDC1, 2, 3, 4, Syndecans (1-4), ITA5, ROBO1, Nectin-4, Nectin-2, LRP1, CD70, Podoplanin, IGF-1R, ABCG2, IBT1, ALK, TEM1, HVEM, TERT, LYPD3, GPR56, IL6RA, DDR1, LIFR, GPR64, S1PR1-4, LRCHD2, NMB, Plexin1/2, PTHR, Semaphorins, Slit3, TACD2, VGFC, VLDLR, VTN 〰️
What we provide
We know precisely…...
how Combotope antibodies interact with its targets
..which sequences are in the target-specific family
..which sequences are non-specific
We offer an attractive win-win partnership business model
Upfront, and milestone payments tied to development and regulatory achievements
Minimum royalties and royalties based on product sales.
Leadership
-
Dr. Klas Ola Blixt
CO-FOUNDER, INVENTOR, & CEO
Ola is the inventor of the Combotope concept and possesses a profound understanding of aberrant glycosylation, enabling the generation of cancer-specific and cancer-selective antibodies. With over 20 years of experience in both basic and applied research across fields such as chemical biology, glycoscience, monoclonal antibodies, and biomarkers, Ola has produced several highly cited publications (h=50) and holds numerous patents. Moreover, Ola brings more than 15 years of management and leadership experience to the table.
-
Dr. Søren Nyboe Jakobsen
CO-FOUNDER, COO
Søren is the inventor or co-inventor of multiple patents in molecular display, selection techniques, and technologies for detecting and characterizing B and T cells. He is the founder and former CEO of Tetramer Shop, which was successfully acquired by 10x Genomics. Throughout his career, Søren has developed foundational IP, platforms, and products at several notable biotech companies, including Novo Nordisk, Nuevolution (acquired by Amgen), Immudex, PokeACell, and 10x Genomics. With extensive experience in startup management and leadership, Søren has been instrumental in driving innovation across the biotech sector.
Combotope Therapeutics ApS
Diplomvej 381
DK-2800 Kongens Lyngby
Denmark
Contact:
olablixt@combotope.com
Company registration (CVR) no. 44308266
